查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000838

心臟即時檢測設備市場：按產品類型、檢體類型、技術、應用和最終用戶分類的全球市場預測，2026-2032年

Cardiac POC Testing Devices Market by Product Type, Sample Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，心臟即時檢測 (POC) 設備市值將達到 16.9 億美元，到 2026 年將成長至 19 億美元，到 2032 年將達到 40 億美元，複合年成長率為 13.01%。

主要市場統計數據
基準年 2025 16.9億美元
預計年份：2026年 19億美元
預測年份 2032 40億美元
複合年成長率 (%) 13.01%

對即時心臟診斷進行了簡潔且引人入勝的概述，重點介紹了臨床要求、操作重點和策略啟動因素。

床邊心臟診斷設備正逐漸成為現代心血管診療路徑中的關鍵工具，重塑臨床醫師檢測和應對急性心臟疾病的方式。這些平台可在患者床邊或床邊提供生物標記訊息，縮短診斷時間，從而加快治療決策。對於許多醫療機構而言，縮短急性冠狀動脈症候群和心臟衰竭加重等疾病的診斷時間是臨床工作的重中之重，而床邊診斷解決方案透過提供快速、可操作的檢測結果，直接助力實現這一目標，並將這些結果整合到急診和住院工作流程中。

技術進步、重新設計的臨床工作流程以及不斷變化的報銷要求如何改變心臟照護現場的採用和效用。

在技​​術創新、醫療模式變革以及對快速準確診斷日益成長的需求的推動下，心臟就地檢驗領域正經歷著一場變革。技術層面，檢測組件的小型化、電化學和光學檢測系統的整合以及免疫檢測的改進，都在同時提升分析性能並縮短反應時間。這些進步正在拓展即時檢測的可靠應用場景，使其涵蓋院前急救和資源匱乏的臨床環境。

評估 2025 年關稅對供應鏈造成的壓力，以及對策略採購的應對措施，這些措施將影響設備可用性、採購經濟性和業務連續性。

貿易政策的發展，包括美國將於2025年實施的關稅調整，為心臟病診療生態系統中的製造商、經銷商和醫療保健採購商帶來了新的考量。關稅正在影響零件採購、定價策略和供應鏈韌性，促使製造商重新評估其採購結構，並探索與替代製造地和供應商的合作。為此，許多公司開始實現供應鏈多元化，以降低對單一國家依賴的風險，並在不影響臨床療效的前提下保持獲利能力。

全面細分分析，重點在於生物標記選擇、最終用戶工作流程要求、檢測技術、檢體偏好和關鍵心臟應用領域。

對心臟就地檢驗市場進行詳細的細分分析，揭示了產品、終端用戶、技術、檢體類型和應用方面的清晰趨勢，這些趨勢全面影響著市場需求和發展重點。產品差異化主要圍繞在生物標記展開，例如腦鈉肽（BNP）、肌酸激酶同工酶（CK-MB）、肌紅蛋白和肌鈣蛋白，其中肌鈣蛋白檢測又可細分為肌鈣蛋白I和肌鈣蛋白T。儘管基於肌鈣蛋白的檢測由於其對心肌損傷的高診斷特異性，仍然是急性胸痛臨床診療路徑的核心，但在心臟衰竭評估中，BNP檢測更為常用。 CK-MB和肌紅蛋白檢測在某些特定情況下仍然效用，例如當補充資訊或歷史對比具有臨床意義時。

在全球範圍內，不同地區的需求差異和醫療保健系統結構決定了照護現場設備的功能重點、部署策略和分銷管道。

區域需求因素和醫療保健系統結構導致全球範圍內床邊心臟診斷的評估和實施方式存在顯著差異。在美洲，急診醫療通訊協定和廣泛的門診網路推動了對可在醫院和診所部署的快速、整合式床邊診斷解決方案的需求。與電子健康記錄的互通性和高效的計費方式在該地區醫療保健系統中通常至關重要，這決定了產品的功能需求和整合服務的性質。

競爭格局由成熟企業、敏捷創新者、策略夥伴關係以及將產品性能與臨床結果聯繫起來的不斷發展的服務模式所驅動。

心臟即時檢測領域的競爭格局由眾多參與者構成，包括傳統診斷設備製造商、專業即時檢測公司以及新興技術參與企業。市場上的成熟企業利用其與醫院和診所建立的穩固關係，提供廣泛的服務網路和豐富的合規經驗，以促進醫院層面的採購和長期服務合約的簽訂。這些企業通常會投資於平台互通性和擴展檢測項目，以增強客戶維繫，並制定支援策略，使用戶能夠使用單一裝置進行多種檢測。

為醫療器材製造商和醫療保健系統提供可操作的策略重點，以加快部署速度、降低供應風險並展現可衡量的臨床和營運價值。

產業領導者若想鞏固其在心臟照護現場市場的地位，應優先考慮結合臨床證據產生、模組化產品設計和穩健的供應鏈策略的策略。投資進行可靠的臨床檢驗研究，以證明產品對病患治療路徑的實際影響，將加速醫院和保險公司的採納。尤其令人信服的是，能夠將檢測結果與縮短住院時間、加速治療決策或提高分診準確性連結起來的證據。同時，允許逐步添加檢測項目和軟體升級的模組化平台，既能幫助客戶保護其投資，又能使供應商有效率地擴展產品系列。

採用嚴謹的混合研究途徑，結合對臨床醫生的訪談、採購洞察、監管趨勢和多方面資訊匹配，以獲得可靠的策略洞察。

本分析所依據的研究採用了混合方法，以確保研究的深度、多方驗證和可操作性。主要研究包括對急診和心臟監護室的臨床醫生、醫院和診所的採購經理以及醫療設備製造商的產品經理進行結構化訪談。這些訪談揭示了實際工作流程需求、採購標準和設備功能優先級，提供了僅憑定量資料集無法捕捉到的細緻觀點。

整合臨床、技術和營運要求，以確定哪些即時心臟技術將實現持續的臨床應用和影響。

總之，在技術進步、臨床對快速決策的需求以及不斷變化的採購優先事項的推動下，床邊心臟診斷在急診和分散式護理模式中日益發揮核心作用。最具影響力的醫療設備將兼具檢查室級的性能、便利的操作性、強大的互通性和供應鏈的韌性。從製造商和經銷商到醫院經營團隊和臨床醫生，整個價值鏈上的相關人員需要就證據生成、用戶體驗和商業性安排達成一致，以最大限度地發揮床邊心臟生物標記檢測的潛力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：心臟即時檢測設備市場：依產品類型分類

  • BNP
  • CK-MB
  • 肌紅蛋白
  • 肌鈣蛋白
    • 肌鈣蛋白 I
    • 肌鈣蛋白T

第9章：心臟即時檢測設備市場－檢體類型

  • 電漿
  • 血清
  • 全血

第10章：心臟即時檢測設備市場：依技術分類

  • 比色法
  • 電化學
  • 免疫檢測
    • 螢光法
    • 側向流

第11章：心臟即時檢測設備市場：依應用領域分類

  • 急性冠狀動脈症候群
  • 心臟衰竭

第12章：心臟即時檢測設備市場：依最終用戶分類

  • 診所
  • 檢查室
  • 醫院
    • 心臟監護病房
    • 急診室

第13章：心臟即時偵測設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：心臟即時檢測設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：心臟即時檢測設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國心臟即時檢測設備市場

第17章：中國心臟即時檢測設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • A. Menarini Diagnostics Srl
  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Alere Inc.
  • Alfa Scientific Designs, Inc.
  • American Screening Corporation Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BIOMERIEUX
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Getein Biotech, Inc.
  • LifeSign LLC.
  • Medtronic plc
  • Nano-Ditech Corp.
  • Nexus Dx, Inc.
  • Nova Biomedical Corporation
  • Polymer Technology Systems, Inc.
  • Precision Biosensor, Inc.
  • PTS Diagnostics
  • QuidelOrtho Corporation
  • Sekisui Medical Co., Ltd.
  • Siemens Healthineers AG
  • Trinity Biotech
  • Werfen, SA
Product Code: MRR-02026C4CB4BE

The Cardiac POC Testing Devices Market was valued at USD 1.69 billion in 2025 and is projected to grow to USD 1.90 billion in 2026, with a CAGR of 13.01%, reaching USD 4.00 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.69 billion
Estimated Year [2026] USD 1.90 billion
Forecast Year [2032] USD 4.00 billion
CAGR (%) 13.01%

A concise yet compelling orientation to point-of-care cardiac diagnostics that frames clinical imperatives, operational priorities, and strategic adoption drivers

Point-of-care cardiac diagnostic devices have emerged as pivotal tools in modern cardiovascular care pathways, reshaping how clinicians detect and respond to acute cardiac events. These platforms deliver biomarker insights at or near the patient bedside, shortening diagnostic timelines and empowering quicker therapeutic decisions. The clinical priority for many providers is to reduce time-to-diagnosis for conditions such as acute coronary syndromes and heart failure exacerbations, and point-of-care solutions contribute directly to that objective by providing rapid, actionable results that integrate into emergency and inpatient workflows.

Operationally, hospitals and clinics value devices that balance analytical performance with ease of use, minimal maintenance, and seamless integration into electronic health records. Advances in assay chemistry and signal detection have improved sensitivity and specificity, which in turn increases clinician confidence in point-of-care results. As a result, adoption is increasingly driven by a combination of clinical utility, workflow compatibility, and total cost of ownership considerations. When stakeholders evaluate strategic investments in cardiac point-of-care technologies, they weigh not only diagnostic accuracy but also device footprint, consumable logistics, staff training requirements, and regulatory pathways that affect long-term operational viability.

Taken together, these factors frame the business case for point-of-care cardiac devices: they are instruments of clinical acceleration and systems efficiency. Moving forward, the ability of manufacturers and health systems to align product design with clinical requirements and reimbursement realities will determine which platforms become standard fixtures in acute care and ambulatory settings.

How technological advances, clinical workflow redesign, and evolving reimbursement expectations are jointly transforming adoption and utility of cardiac point-of-care diagnostics

The landscape of cardiac point-of-care testing is undergoing transformative shifts driven by technological innovation, changing care models, and heightened expectations for rapid diagnostic precision. On the technology front, miniaturization of assay components, integration of electrochemical and optical detection systems, and refinement of immunoassay formats have collectively improved analytical performance while reducing time-to-result. These developments expand the clinical contexts where point-of-care testing can be reliably deployed, including pre-hospital triage and resource-constrained clinic environments.

Concurrently, care delivery paradigms are evolving; emergency departments and cardiac care units increasingly rely on faster diagnostic information to prioritize patients and manage bed flow. This clinical pressure, coupled with a broader move toward decentralized care, elevates demand for robust point-of-care platforms that deliver laboratory-grade results without the delays associated with central labs. Meanwhile, payers and health systems are scrutinizing value, favoring solutions that demonstrably reduce downstream costs through earlier intervention and reduced admissions. The cumulative effect is a shift from early adopter experimentation to mainstream clinical integration.

Regulatory and reimbursement frameworks are also adapting, with agencies clarifying performance expectations for near-patient devices and payers refining coverage policies that reflect clinical evidence. As a result, manufacturers that can demonstrate consistent analytical validity, operational resilience, and measurable clinical impact will secure stronger uptake. In summary, technological advancement, clinical workflow redesign, and economic accountability are converging to transform how cardiac point-of-care diagnostics contribute to faster, more effective care.

Assessment of 2025 tariff-driven supply-chain pressures and strategic sourcing responses shaping device availability, procurement economics, and operational continuity

Trade policy developments, including tariff adjustments introduced in the United States in 2025, have created a new set of considerations for manufacturers, distributors, and healthcare purchasers in the cardiac point-of-care ecosystem. Tariffs influence component sourcing, pricing strategies, and supply-chain resilience, prompting manufacturers to reassess procurement footprints and to explore alternative manufacturing locations or supplier partnerships. In response, many firms have initiated supply-chain diversification efforts to mitigate single-country exposure and to preserve margin structures without compromising clinical performance.

These tariff-driven pressures also affect distribution economics. Distributors and hospital procurement teams are recalibrating contract terms and inventory strategies to accommodate potential cost variability. For some vendors, the tariff environment accelerated plans to localize assembly or to secure long-term component agreements, which helps stabilize unit costs and shortens replenishment cycles. Additionally, tariff impacts have prompted closer scrutiny of input cost breakdowns and encouraged transparency between suppliers and customers so that adjustments can be anticipated rather than reacted to.

From a clinical operations perspective, the specter of elevated costs has encouraged health systems to prioritize devices that offer clear workflow efficiencies and that reduce downstream resource utilization, such as shorter emergency department stays or fewer unnecessary admissions. Ultimately, tariffs serve as a catalyst for strategic supply-chain planning, compelling stakeholders to balance cost containment with uninterrupted access to high-quality diagnostics and to consider operational levers that sustain clinical capacity while absorbing economic shifts.

A comprehensive segmentation analysis highlighting biomarker selection, end-user workflow demands, detection technologies, sample preferences, and primary cardiac applications

A nuanced segmentation of the cardiac point-of-care testing market reveals distinct product, end-user, technological, sample-type, and application dynamics that collectively shape demand and development priorities. Product differentiation centers on biomarkers such as BNP, CK-MB, Myoglobin, and the troponins, with troponin assays further divided into Troponin I and Troponin T. Troponin-based testing remains central to acute chest pain pathways given its diagnostic specificity for myocardial injury, while BNP assays are prioritized in heart failure assessment scenarios. CK-MB and myoglobin retain utility in certain contexts where complementary information or historical comparison is clinically useful.

End-user segmentation spans clinics, diagnostic laboratories, and hospitals, the latter encompassing both cardiac care units and emergency departments. Emergency settings prioritize speed and ruggedized workflows, whereas cardiac care units emphasize serial measurement capabilities and integration with continuous monitoring systems. Clinics and outpatient centers value compact, low-maintenance devices that facilitate triage and follow-up without heavy laboratory overhead. Diagnostic laboratories that adopt point-of-care platforms often do so to offload high-throughput analyzers during peak demand or to extend services to satellite sites.

Technological differentiation includes colorimetric, electrochemical, and immunoassay approaches, with immunoassays further divided into fluorescence-based and lateral flow formats. Colorimetric methods offer simplicity and cost advantages for certain analytes, electrochemical platforms excel in miniaturized, low-power architectures, and immunoassays deliver the sensitivity required for low-abundance cardiac biomarkers. Sample-type considerations cover plasma, serum, and whole blood; whole blood compatibility increases usability at the bedside by eliminating centrifugation steps, while plasma and serum samples are preferred when laboratory integration and standardized processing are required. Application-wise, devices are developed primarily for acute coronary syndrome and heart failure use cases, each imposing different sensitivity, turnaround time, and longitudinal monitoring requirements. Understanding these segmentation layers allows stakeholders to align product design, clinical validation, and commercialization strategies with the operational realities of intended end users.

Regional demand and health-system architecture differences that dictate point-of-care device feature priorities, deployment strategies, and adoption pathways across global territories

Regional demand drivers and health-system architectures create meaningful variation in how point-of-care cardiac diagnostics are evaluated and implemented across global geographies. In the Americas, emergency care protocols and extensive outpatient networks drive demand for rapid, integrated point-of-care solutions that can be deployed across hospitals and ambulatory clinics. Health systems in this region often emphasize interoperability with electronic health records and streamlined billing practices, which shapes product feature requirements and integration services.

In Europe, Middle East & Africa, heterogeneous regulatory environments and varying levels of laboratory infrastructure produce a diverse set of adoption pathways. High-acuity hospitals in major European centers prioritize analytical rigor and regulatory compliance, whereas resource-limited settings in parts of the Middle East and Africa adopt point-of-care platforms to extend diagnostic capacity where centralized laboratories are scarce. In these contexts, devices that combine robustness, minimal maintenance, and clear training materials achieve broader traction.

The Asia-Pacific region demonstrates rapid uptake driven by expanding acute care facilities, growing investment in decentralized care models, and strong interest in localization of manufacturing and distribution. Diverse clinical settings-from metropolitan tertiary hospitals to decentralized community clinics-create demand for both high-throughput and handheld point-of-care solutions. Across regions, purchasers look for validated clinical performance, reliable supply chains, and demonstrable contributions to improved patient flow and clinical decision-making, but the relative weighting of these criteria varies based on local health-system priorities and reimbursement frameworks.

Competitive landscape dynamics driven by incumbents, agile innovators, strategic partnerships, and evolving service models that align product performance with clinical outcomes

Competitive dynamics in the cardiac point-of-care testing sector are shaped by a mix of legacy diagnostic manufacturers, specialized point-of-care firms, and emerging technology entrants. Market incumbents leverage established relationships with hospitals and clinics, providing broad service networks and deep regulatory experience that facilitate hospital-level procurement and long-term service agreements. These organizations often invest in platform interoperability and extended menu capabilities to reinforce customer retention and to support multi-assay strategies within a single device footprint.

Specialized point-of-care firms focus on speed-to-result and compact device design, pursuing niche adoption opportunities in emergency medicine, rural healthcare, and pre-hospital care. Their agility in product development enables rapid iteration on assay formats and user interfaces, although scaling distribution and service networks remains a logistical focus. New entrants leveraging novel detection chemistries or digital analytics introduce competitive pressure by promising either analytical improvements or enhanced user experiences that reduce training burdens and operator variability.

Strategic partnerships and acquisition activity continue to shape the competitive landscape as larger firms supplement portfolios with point-of-care capabilities and as innovators seek channel access and regulatory expertise. In parallel, service models such as reagent leasing, subscription pricing, or outcome-based contracts are being explored to align vendor incentives with clinical impact. Collectively, these competitive behaviors drive continuous improvement in device performance, user experience, and commercial flexibility, benefitting health systems that require both reliability and adaptability.

Actionable strategic priorities for device makers and health systems to enhance adoption, mitigate supply risks, and demonstrate measurable clinical and operational value

Industry leaders seeking to strengthen their position in the cardiac point-of-care market should prioritize a combination of clinical evidence generation, modular product design, and resilient supply-chain strategies. Investing in robust clinical validation studies that demonstrate real-world impact on patient pathways will accelerate adoption by hospitals and payers; evidence that links testing to reduced length of stay, faster therapeutic decisions, or improved triage accuracy is particularly persuasive. Concurrently, modular platforms that allow incremental assay additions and software upgrades help customers protect their investment while enabling vendors to scale product portfolios efficiently.

On the operational side, diversifying component supply and considering regional assembly options will mitigate tariff and logistics-related vulnerabilities. Transparent engagement with health-system procurement teams to align total cost of ownership considerations and to offer flexible commercial models-such as reagent-as-a-service or outcome-linked contracts-can lower adoption barriers. From a user experience perspective, simplifying interfaces, minimizing maintenance needs, and providing comprehensive training resources will reduce operational friction and improve data quality at the point of care.

Finally, pursuing interoperability standards and partnering with electronic health record providers enhances clinical workflow integration and supports broader institutional adoption. By combining clinical validation, flexible commercialization, resilient sourcing, and a relentless focus on user-centered design, leaders can maximize adoption potential and deliver measurable value to care teams and patients alike.

A rigorous mixed-methods research approach combining clinician interviews, procurement insights, regulatory synthesis, and multi-source triangulation for reliable strategic intelligence

The research underpinning this analysis employed a mixed-methods approach to ensure depth, triangulation, and practical relevance. Primary research included structured interviews with clinicians from emergency departments and cardiac care units, procurement leaders from hospitals and clinics, and product managers across device manufacturers. These conversations illuminated real-world workflow needs, procurement criteria, and device feature priorities, offering nuanced perspectives that quantitative datasets alone cannot capture.

Secondary research synthesized regulatory guidance, clinical practice guidelines, and peer-reviewed literature to contextualize biomarker utility, device performance expectations, and care-pathway integration. Information on technology trends and supply-chain developments was corroborated through industry briefings and publicly available regulatory filings. Where possible, methodology cross-validation was achieved by comparing primary insights with secondary sources to identify consistent themes and to flag divergent viewpoints for deeper inquiry.

Analytical rigor was maintained through systematic data cleaning, thematic coding of qualitative interviews, and structured synthesis of findings to produce actionable insights. Quality control steps included peer review of interpretive conclusions and verification of technical claims with subject-matter experts. The result is a multi-perspective assessment designed to support strategic decisions across clinical, commercial, and operational domains, with transparent methods that facilitate reproducibility and targeted follow-up research when deeper granularity is required.

Synthesis of clinical, technological, and operational imperatives that will determine which point-of-care cardiac technologies achieve sustained clinical integration and impact

In conclusion, point-of-care cardiac diagnostics are positioned to play an increasingly central role in acute care and decentralized care models, driven by technological progress, clinical need for rapid decision-making, and evolving procurement priorities. The most impactful devices will be those that pair laboratory-quality performance with operational simplicity, robust interoperability, and supply-chain resilience. Stakeholders across the value chain-from manufacturers and distributors to hospital leaders and clinicians-must align on evidence generation, user experience, and commercial arrangements to realize the full potential of bedside cardiac biomarker testing.

As clinical environments continue to prioritize speed, accuracy, and cost-effectiveness, the ability to demonstrate tangible improvements in patient flow and clinical outcomes will be a decisive factor in broader adoption. Simultaneously, geopolitical and policy developments introduce supply-chain considerations that organizations must proactively address through diversified sourcing and localized capabilities. Looking ahead, the intersection of refined assay chemistries, intelligent device platforms, and outcome-oriented commercial models will define the next phase of growth and integration for cardiac point-of-care testing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac POC Testing Devices Market, by Product Type

  • 8.1. BNP
  • 8.2. CK-MB
  • 8.3. Myoglobin
  • 8.4. Troponin
    • 8.4.1. Troponin I
    • 8.4.2. Troponin T

9. Cardiac POC Testing Devices Market, by Sample Type

  • 9.1. Plasma
  • 9.2. Serum
  • 9.3. Whole Blood

10. Cardiac POC Testing Devices Market, by Technology

  • 10.1. Colorimetric
  • 10.2. Electrochemical
  • 10.3. Immunoassay
    • 10.3.1. Fluorescence
    • 10.3.2. Lateral Flow

11. Cardiac POC Testing Devices Market, by Application

  • 11.1. Acute Coronary Syndrome
  • 11.2. Heart Failure

12. Cardiac POC Testing Devices Market, by End User

  • 12.1. Clinics
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospital
    • 12.3.1. Cardiac Care Unit
    • 12.3.2. Emergency Department

13. Cardiac POC Testing Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiac POC Testing Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiac POC Testing Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cardiac POC Testing Devices Market

17. China Cardiac POC Testing Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. A. Menarini Diagnostics S.r.l.
  • 18.6. Abbott Laboratories
  • 18.7. ACON Laboratories, Inc.
  • 18.8. Alere Inc.
  • 18.9. Alfa Scientific Designs, Inc.
  • 18.10. American Screening Corporation Inc.
  • 18.11. Becton, Dickinson and Company
  • 18.12. Bio-Rad Laboratories, Inc.
  • 18.13. BIOMERIEUX
  • 18.14. Danaher Corporation
  • 18.15. F. Hoffmann-La Roche AG
  • 18.16. Getein Biotech, Inc.
  • 18.17. LifeSign LLC.
  • 18.18. Medtronic plc
  • 18.19. Nano-Ditech Corp.
  • 18.20. Nexus Dx, Inc.
  • 18.21. Nova Biomedical Corporation
  • 18.22. Polymer Technology Systems, Inc.
  • 18.23. Precision Biosensor, Inc.
  • 18.24. PTS Diagnostics
  • 18.25. QuidelOrtho Corporation
  • 18.26. Sekisui Medical Co., Ltd.
  • 18.27. Siemens Healthineers AG
  • 18.28. Trinity Biotech
  • 18.29. Werfen, S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC POC TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC POC TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)